News headlines about Matinas BioPharma Holdings (NASDAQ:MTNB) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Matinas BioPharma Holdings earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.6096532714168 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
MTNB has been the subject of a number of recent analyst reports. Aegis reiterated a “positive” rating and set a $8.00 target price on shares of Matinas BioPharma Holdings in a research report on Tuesday, March 28th. Roth Capital started coverage on Matinas BioPharma Holdings in a research report on Monday, July 10th. They set a “buy” rating and a $9.00 target price for the company. Finally, Maxim Group restated a “buy” rating and set a $6.00 price objective on shares of Matinas BioPharma Holdings in a research report on Monday, March 27th.
Shares of Matinas BioPharma Holdings (MTNB) traded down 0.69% during mid-day trading on Thursday, hitting $1.44. The company had a trading volume of 16,934 shares. Matinas BioPharma Holdings has a one year low of $0.62 and a one year high of $3.99. The company’s market capitalization is $131.61 million. The company’s 50-day moving average is $2.09 and its 200 day moving average is $2.61.
Matinas BioPharma Holdings (NASDAQ:MTNB) last issued its quarterly earnings results on Tuesday, May 16th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.21. Matinas BioPharma Holdings had a negative return on equity of 1,227.85% and a negative net margin of 30,034.20%. The firm had revenue of $0.02 million for the quarter. On average, equities research analysts forecast that Matinas BioPharma Holdings will post ($0.26) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Matinas BioPharma Holdings (MTNB) Receiving Somewhat Positive Press Coverage, Study Shows” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://sportsperspectives.com/2017/07/20/matinas-biopharma-holdings-mtnb-receiving-somewhat-positive-press-coverage-study-shows.html.
About Matinas BioPharma Holdings
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.